These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38924513)

  • 41. Perioperative outcomes of neoadjuvant immunotherapy plus chemotherapy and neoadjuvant chemoradiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective comparative cohort study.
    Zhang H; Zhang Z; Yang L; Wu B; Chen Y; He H; Li C; Lin W; Lin J
    J Thorac Dis; 2023 Mar; 15(3):1279-1288. PubMed ID: 37065590
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of neoadjuvant chemotherapy or chemoradiotherapy plus immunotherapy for locally resectable esophageal squamous cell carcinoma.
    Yang G; Yue H; Zhang X; Zeng C; Tan L; Zhang X
    Front Immunol; 2024; 15():1336798. PubMed ID: 38779667
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CD44, SHH and SOX2 as novel biomarkers in esophageal cancer patients treated with neoadjuvant chemoradiotherapy.
    Honing J; Pavlov KV; Mul VE; Karrenbeld A; Meijer C; Faiz Z; Smit JK; Hospers GA; Burgerhof JG; Kruyt FA; Kleibeuker JH; Plukker JT
    Radiother Oncol; 2015 Oct; 117(1):152-8. PubMed ID: 26364884
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT).
    van den Ende T; de Clercq NC; van Berge Henegouwen MI; Gisbertz SS; Geijsen ED; Verhoeven RHA; Meijer SL; Schokker S; Dings MPG; Bergman JJGHM; Haj Mohammad N; Ruurda JP; van Hillegersberg R; Mook S; Nieuwdorp M; de Gruijl TD; Soeratram TTD; Ylstra B; van Grieken NCT; Bijlsma MF; Hulshof MCCM; van Laarhoven HWM
    Clin Cancer Res; 2021 Jun; 27(12):3351-3359. PubMed ID: 33504550
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Composition of gastrointestinal microbiota in association with treatment response in individuals with metastatic castrate resistant prostate cancer progressing on enzalutamide and initiating treatment with anti-PD-1 (pembrolizumab).
    Peiffer LB; White JR; Jones CB; Slottke RE; Ernst SE; Moran AE; Graff JN; Sfanos KS
    Neoplasia; 2022 Oct; 32():100822. PubMed ID: 35908379
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer.
    Serna G; Ruiz-Pace F; Hernando J; Alonso L; Fasani R; Landolfi S; Comas R; Jimenez J; Elez E; Bullman S; Tabernero J; Capdevila J; Dienstmann R; Nuciforo P
    Ann Oncol; 2020 Oct; 31(10):1366-1375. PubMed ID: 32569727
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analysis of Gut Microbiota Signature and Microbe-Disease Progression Associations in Locally Advanced Non-Small Cell Lung Cancer Patients Treated With Concurrent Chemoradiotherapy.
    Xi Y; Liu F; Qiu B; Li Y; Xie X; Guo J; Wu L; Liang T; Wang D; Wang J; Chen M; Xue L; Ding Y; Zhang J; Wu Q; Liu H
    Front Cell Infect Microbiol; 2022; 12():892401. PubMed ID: 35719339
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical predictors of pathologically response after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma: long term outcomes of a phase II study.
    Tan Z; Yang H; Wen J; Luo K; Liu Q; Hu Y; Zhang L; Liu M; Yun J; Fu J
    J Thorac Dis; 2018 Sep; 10(9):5254-5259. PubMed ID: 30416772
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Validation of a Nomogram Predicting Survival After Trimodality Therapy for Esophageal Cancer.
    Goense L; Merrell KW; Arnett AL; Hallemeier CL; Meijer GJ; Ruurda JP; Hofstetter WL; van Hillegersberg R; Lin SH
    Ann Thorac Surg; 2018 Nov; 106(5):1541-1547. PubMed ID: 29932887
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for clinical node-negative esophageal carcinoma.
    Gao HJ; Wei YC; Gong L; Ge N; Han B; Shi GD; Yu ZT
    Thorac Cancer; 2020 Sep; 11(9):2618-2629. PubMed ID: 32755068
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.
    Aden K; Rehman A; Waschina S; Pan WH; Walker A; Lucio M; Nunez AM; Bharti R; Zimmerman J; Bethge J; Schulte B; Schulte D; Franke A; Nikolaus S; Schroeder JO; Vandeputte D; Raes J; Szymczak S; Waetzig GH; Zeuner R; Schmitt-Kopplin P; Kaleta C; Schreiber S; Rosenstiel P
    Gastroenterology; 2019 Nov; 157(5):1279-1292.e11. PubMed ID: 31326413
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer.
    Teng H; Wang Y; Sui X; Fan J; Li S; Lei X; Shi C; Sun W; Song M; Wang H; Dong D; Geng J; Zhang Y; Zhu X; Cai Y; Li Y; Li B; Min Q; Wang W; Zhan Q
    Cancer Cell; 2023 Jan; 41(1):124-138.e6. PubMed ID: 36563680
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 54. Nomogram for predicting pathologic complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Liu G; Chen T; Zhang X; Hu B; Yu J
    Cancer Med; 2024 Mar; 13(5):e7075. PubMed ID: 38477511
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-throughput DNA extraction strategy for fecal microbiome studies.
    Isokääntä H; Tomnikov N; Vanhatalo S; Munukka E; Huovinen P; Hakanen AJ; Kallonen T
    Microbiol Spectr; 2024 Jun; 12(6):e0293223. PubMed ID: 38747618
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gross Tumor Volume Predicts Survival and Pathological Complete Response of Locally Advanced Esophageal Cancer After Neoadjuvant Chemoradiotherapy.
    Wang R; Zhou X; Liu T; Lin S; Wang Y; Deng X; Wang W
    Front Oncol; 2022; 12():898383. PubMed ID: 35747837
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of Neoadjuvant Immunotherapy Plus Chemotherapy versus Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study.
    Zhao J; Hao S; Tian J; Li Y; Han D
    J Inflamm Res; 2023; 16():3351-3363. PubMed ID: 37576156
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diversity of Duodenal and Rectal Microbiota in Biopsy Tissues and Luminal Contents in Healthy Volunteers.
    Li G; Yang M; Zhou K; Zhang L; Tian L; Lv S; Jin Y; Qian W; Xiong H; Lin R; Fu Y; Hou X
    J Microbiol Biotechnol; 2015 Jul; 25(7):1136-45. PubMed ID: 25737115
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of therapeutic outcomes in esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: A prospective observational cohort study.
    Liu YW; Lee JY; Wang YK; Chen YH; Fang PT; Chou SH; Chen MH; Bai LY; Yen CJ; Wu MT; Wu IC
    J Formos Med Assoc; 2024 Jan; 123(1):106-115. PubMed ID: 37385933
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fecal microbiome composition and diversity of cryopreserved canine stool at different duration and storage conditions.
    Barko P; Nguyen-Edquilang J; Williams DA; Gal A
    PLoS One; 2024; 19(2):e0294730. PubMed ID: 38324560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.